MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$6,814K
Free Cash flow
-$7,603K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Gross proceeds from secondary pu...
Maturities of marketable securit...
Stock-based compensation expense
Others
Negative Cash Flow Breakdown
Change in fair value of warrant ...
Purchases of marketable securiti...
Net loss
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-1,722
-12,823
-14,668
-6,010
Depreciation expense
6
8
10
10
Loss on disposal of assets
0
-18
-
-
Stock-based compensation expense
2,877
754
777
730
Change in fair value of warrant liability
-7,977
4,780
7,768
-1,067
Amortization of operating lease right of use asset
145
203
141
138
Amortization of investments in marketable securities
-33
12
-
-
Prepaid expense and other current assets
936
1,267
98
394
Accounts payable and accrued liabilities
180
2,285
-1,814
775
Operating lease liability
-144
-211
-148
-144
Net cash used in operating activities
-7,604
-6,241
-8,032
-5,962
Purchases of marketable securities
2,999
5,149
12,071
-
Maturities of marketable securities
2,975
-
-
-
Purchases of property and equipment
-1
8
0
2
Realized gain on marketable securities
0
-2
-
-
Net cash used in investing activities
-23
-5,155
-12,071
-2
Gross proceeds from secondary public offering
14,888
20,174
6,811
27,147
Commissions paid on secondary public offering
447
605
205
814
Payments on financed insurance policies
-
-
0
1
Proceeds from exercise of warrants
-
-
0
0
Net cash provided by financing activities
14,441
19,569
6,606
26,332
Net (decrease) increase in cash and cash equivalents
6,814
8,173
-13,497
20,368
Cash and cash equivalents at the beginning of the period
37,371
29,198
42,695
26,142
Cash and cash equivalents at the end of the period
44,185
37,371
29,198
42,695
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Gross proceeds from
secondary public offering
$14,888K
(17.93%↑ Y/Y)
Net cash provided by
financing activities
$14,441K
(6.73%↑ Y/Y)
Canceled cashflow
$447K
Net (decrease)
increase in cash and cash...
$6,814K
(278.61%↑ Y/Y)
Canceled cashflow
$7,627K
Commissions paid on
secondary public offering
$447K
(17.94%↑ Y/Y)
Stock-based compensation
expense
$2,877K
(153.70%↑ Y/Y)
Accounts payable and
accrued liabilities
$180K
(112.28%↑ Y/Y)
Amortization of operating
lease right of use...
$145K
(-44.02%↓ Y/Y)
Depreciation expense
$6K
(-57.14%↓ Y/Y)
Maturities of marketable
securities
$2,975K
Purchases of property and
equipment
-$1K
(-104.55%↓ Y/Y)
Net cash used in
operating activities
-$7,604K
(56.10%↑ Y/Y)
Net cash used in
investing activities
-$23K
(-4.55%↓ Y/Y)
Canceled cashflow
$3,208K
Canceled cashflow
$2,976K
Change in fair value of
warrant liability
-$7,977K
(8.54%↑ Y/Y)
Purchases of marketable
securities
$2,999K
Net loss
-$1,722K
(70.70%↑ Y/Y)
Prepaid expense and
other current assets
$936K
(-60.87%↓ Y/Y)
Operating lease liability
-$144K
(47.25%↑ Y/Y)
Amortization of investments
in marketable...
-$33K
Buy us a coffee
Unicycive Therapeutics, Inc. (UNCY)
Unicycive Therapeutics, Inc. (UNCY)